Wells Fargo
RUBY

Wells Fargo’s Rubius Therapeutics, Inc RUBY Stock Holding History

Wells Fargo’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-314
Closed -$55 – 7860
2022
Q4 		$55 Buy
314
+8
+3% +$2 ﹤0.01% 6983
2022
Q3 		$0 Buy
306
+28
+10% +$21 ﹤0.01% 7782
2022
Q2 		$0 Sell
278
-43,615
-99% -$73.2K ﹤0.01% 7878
2022
Q1 		$242K Sell
43,893
-13,888
-24% -$88.2K ﹤0.01% 4875
2021
Q4 		$559K Buy
57,781
+10,300
+22% +$143K ﹤0.01% 4574
2021
Q3 		$848K Buy
47,481
+2,207
+5% +$48K ﹤0.01% 4349
2021
Q2 		$1.1M Buy
45,274
+37,905
+514% +$948K ﹤0.01% 4143
2021
Q1 		$195K Sell
7,369
-24,028
-77% -$351K ﹤0.01% 5164
2020
Q4 		$238K Buy
31,397
+12,894
+70% +$76.6K ﹤0.01% 4989
2020
Q3 		$93K Sell
18,503
-57
-0.3% -$302 ﹤0.01% 5297
2020
Q2 		$111K Sell
18,560
-469
-2% -$2.77K ﹤0.01% 5181
2020
Q1 		$84K Sell
19,029
-323
-2% -$2.4K ﹤0.01% 5149
2019
Q4 		$184K Sell
19,352
-1,150
-6% -$11.1K ﹤0.01% 5006
2019
Q3 		$161K Buy
20,502
+1,180
+6% +$13.8K ﹤0.01% 5089
2019
Q2 		$305K Sell
19,322
-1,854
-9% -$29.9K ﹤0.01% 4723
2019
Q1 		$383K Buy
21,176
+15,141
+251% +$232K ﹤0.01% 4485
2018
Q4 		$97K Buy
6,035
+2,614
+76% +$47.7K ﹤0.01% 5296
2018
Q3 		$82K Buy
+3,421
New +$78.2K ﹤0.01% 5432

Other funds holding RUBY

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return

Wells Fargo's RUBY Position: Q1 2023 in Review

Wells Fargo sold out of Rubius Therapeutics, Inc (RUBY) in Q1 2023, closing a stake of 314 shares — an estimated $55 sold.

Wells Fargo first reported a position in RUBY in Q3 2018 and held it in 18 quarters. The position peaked at $1.1M in Q2 2021. 7 funds tracked by Wall St. Rank hold RUBY as of Q1 2023.

  • Wells Fargo reported no remaining Rubius Therapeutics, Inc position as of Q1 2023 after selling out during the quarter.
  • Wells Fargo sold 314 Rubius Therapeutics, Inc shares in Q1 2023, an estimated $55.
  • Wells Fargo first reported a position in Rubius Therapeutics, Inc in Q3 2018 and held it in 18 quarters.
  • Wells Fargo's Rubius Therapeutics, Inc position peaked at $1.1M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q1 2023.

Based on Wells Fargo's 13F filing for Q1 2023, filed 12 May 2023.